Abstract
Moxifloxacin-resistant Mycobacterium tuberculosis mutants were selected in vitro using different concentrations of moxifloxacin. gyrA mutations at codons 88 and 94 were associated with resistance (defined as an MIC of ≥2 μg/ml) (P < 0.0001 and P = 0.0053, respectively). Despite the presence of gyrA mutations, moxifloxacin significantly impedes bacterial growth, supporting its use for the treatment of ofloxacin-resistant M. tuberculosis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antitubercular Agents / pharmacology*
-
Bacterial Proteins / genetics*
-
DNA Gyrase / genetics*
-
Drug Resistance, Bacterial / genetics
-
Fluoroquinolones / pharmacology*
-
Microbial Sensitivity Tests
-
Moxifloxacin
-
Mutation
-
Mycobacterium tuberculosis / drug effects*
-
Mycobacterium tuberculosis / genetics
Substances
-
Antitubercular Agents
-
Bacterial Proteins
-
Fluoroquinolones
-
DNA Gyrase
-
Moxifloxacin